Current stock page

Catalysts

ABBV Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareDrug Manufacturers - GeneralScore data as of Nov 13, 2026

ABBVAbbVie Inc.

Healthcare / Drug Manufacturers - General

Leader

Strong Relative Position

BullishEdge 8/10
$295.03+$0.58 (+0.20%)

Latest quote

  • Momentum
    89
  • Value
    27
  • Quality
    61
  • Risk resilience
    84
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 3, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 67/100

Momentum 89/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 47.04%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 89/100AIQ Edge 8/10 Strong Relative Position
Beat rate
88%
7 of 8 reported periods
Average surprise
-1.0%
Across covered historical reports
Latest result
+2.4%
Oct 30, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 30, 2026—$3.73$3.82+2.4%$17.32B$17.4B
Jul 31, 2026—$3.61$3.65+1.1%$16.8B$16.99B
Apr 29, 2026—$2.59$2.65+2.3%$14.72B$15B
Feb 4, 2026—$2.65$2.71+2.3%$16.41B$16.62B
Oct 31, 2025—$1.77$1.86+5.1%$15.59B$15.78B
Jul 31, 2025—$2.88$2.97+3.1%$15.03B$15.42B
Apr 25, 2025—$2.38$2.46+3.4%$12.93B$13.34B
Jan 31, 2025—$2.98$2.16-27.5%$14.83B$15.1B

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
23
Buy
5
Hold
1
Sell
12-month analyst target
$314.79
+6.70% versus current price
Based on 29 analyst observations. Targets are estimates, not predictions.
Low target
$275.00
-6.79% vs latest price
Average target
$314.79
+6.70% vs latest price
High target
$340.00
+15.24% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 3, 2027

Next known earnings or reporting date.

EPS estimate$3.89

Current analyst expectation for the upcoming report.

Revenue estimate$18.34B

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score89

Where event reaction would show up first.

AIQ score67/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
29
Average target
$314.79
Target upside
6.70%
Target range
$275.00 - $340.00
90-day revisions
-2

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
0
Negative
0
zacks.com · Nov 11, 2026

Top Analyst Reports for NVIDIA, Walmart & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corp. (NVDA), Walmart Inc. (WMT), AbbVie Inc. (ABBV) as well as two micro-cap stocks, Pioneer Bancorp, Inc. (PBFS) and Aspira Women's Health Inc. (AWHL).

insidermonkey.com · Nov 8, 2026

Is AbbVie Inc. (ABBV) the Best Healthcare Stock to Buy Following the 2026 Democratic Midterm Sweep?

We just published the list of the 10 Best Healthcare and Insurance Stocks To Buy Following the 2026 Democratic Midterm Sweep and AbbVie Inc. (ABBV) takes the 10th spot on the list.

seekingalpha.com · Oct 30, 2026

AbbVie Inc. (ABBV) Q3 2026 Earnings Call Transcript

AbbVie Inc. (ABBV) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDTCompany ParticipantsElizabeth Shea - Senior Vice President of Investor RelationsRobert...

rttnews.com · Oct 30, 2026

AbbVie Raises FY26 Adj. EPS Outlook; Boost Dividend 5.2% - Update

While reporting financial results for the third quarter on Friday, biopharmaceutical company AbbVie, Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2026, based on strong outlook and significant momentum.

Open full news and sentiment

ABBV Catalysts FAQ

What are the next catalysts for ABBV stock?

ABBV's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ABBV stock?

Upcoming events that could move ABBV include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ABBV's next earnings report affect the stock?

ABBV's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ABBV stock higher?

ABBV could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ABBV stock?

ABBV could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.